PCC

Podiatry Content Connection and Mile High Orthotics Lab Inc. Partner to Boost Orthotics Marketing

Retrieved on: 
Tuesday, January 30, 2024

Since its inception in 2007, Mile High Orthotics Lab, Inc. has specialized in manufacturing custom foot orthotics.

Key Points: 
  • Since its inception in 2007, Mile High Orthotics Lab, Inc. has specialized in manufacturing custom foot orthotics.
  • "We are excited to partner with Mile High Orthotics Lab and bring our innovative SOLE Marketing™ program to more podiatrists and chiropodists," says Jeffrey Hartman, CEO of Podiatry Content Connection.
  • To celebrate this partnership, Podiatry Content Connection is offering an exclusive 25% discount on the SOLE Marketing™ program to podiatrists who purchase from Mile High Orthotics Lab Inc.
  • For more information about the SOLE Marketing™ program and the partnership between Podiatry Content Connection and Mile High Orthotics Lab Inc., please contact PCC at 718-475-9449 or visit PodiatryCC.com.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Wednesday, January 24, 2024

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • Biocytogen’s fully human antibody sequences were generated by proprietary RenMice strains, each engineered to lack a certain drug target gene.
  • RenMice-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Retrieved on: 
Tuesday, January 23, 2024

RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.

Key Points: 
  • RenBiologics business will cover out-licensing/co-development of the company’s extensive library of fully human antibodies, as well as licensing of RenMice®, the company’s fully human antibody/TCR discovery platforms.
  • The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company’s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
  • RenMice®-derived fully human antibodies can be developed into novel therapies to treat numerous cancers, inflammatory and autoimmune diseases, infectious diseases, metabolic diseases, cardiovascular diseases, and neurological diseases.
  • Biocytogen offers licensing and flexible partnering models for its RenMice fully human antibody/TCR discovery platforms.

Podiatry Content Connection Announces Strategic Partnership with SOLO Labs to Boost Orthotics Marketing

Retrieved on: 
Wednesday, January 24, 2024

METUCHEN, N.J., Jan. 24, 2024 /PRNewswire/ -- Podiatry Content Connection (PCC), a leader in digital marketing solutions for the podiatric community, proudly announces its new partnership with SOLO Labs, a renowned custom orthotics manufacturer.

Key Points: 
  • METUCHEN, N.J., Jan. 24, 2024 /PRNewswire/ -- Podiatry Content Connection (PCC), a leader in digital marketing solutions for the podiatric community, proudly announces its new partnership with SOLO Labs, a renowned custom orthotics manufacturer.
  • This collaboration marks a significant step forward in enhancing the marketing and sales of custom foot orthotics across the U.S.
    Podiatry Content Connection & SOLO Labs partner to enhance orthotics awareness, marketing & sales across the U.S.
  • In celebration of this partnership, Podiatry Content Connection is excited to offer an exclusive opportunity for podiatrists and chiropodists.
  • It's a shared vision of enhancing podiatric care through quality products and innovative marketing," says Jeffrey Hartman, CEO of Podiatry Content Connection.

PyroGenesis Announces Improved Economics for Fumed Silica Reactor Project

Retrieved on: 
Thursday, January 11, 2024

As stated in PyroGenesis’ news release dated November 9, 2023 , the production of the fumed silica reactor pilot plant is already underway, with a planned completion by Q2 2024.

Key Points: 
  • As stated in PyroGenesis’ news release dated November 9, 2023 , the production of the fumed silica reactor pilot plant is already underway, with a planned completion by Q2 2024.
  • The FSR, another plasma-based process developed by PyroGenesis, converts quartz into commercial-grade fumed silica (or Pyrogenic Silica) in a single and eco-friendly step.
  • PyroGenesis’ involvement in developing fumed silica from quartz is part of PyroGenesis’ three-tiered solution ecosystem that aligns with economic drivers that are key to global heavy industry.
  • Management has calculated the Payback for the Fumed Silica Reactor (FSR) based on operational data accumulated over the years.

FARSIGHT Awarded WBENC's Women-Owned Small Business and Women’s Business Enterprise Certifications

Retrieved on: 
Tuesday, January 9, 2024

FARSIGHT , a leadership development and coaching consultancy, today announced that it has been awarded the Women-Owned Small Business (WOSB) and the Women’s Business Enterprise (WBE) certifications from the Women's Business Enterprise National Council (WBENC) – an U.S. Small Business Association (SBA) certifier.

Key Points: 
  • FARSIGHT , a leadership development and coaching consultancy, today announced that it has been awarded the Women-Owned Small Business (WOSB) and the Women’s Business Enterprise (WBE) certifications from the Women's Business Enterprise National Council (WBENC) – an U.S. Small Business Association (SBA) certifier.
  • These certifications recognize the exceptional and distinct capabilities of FARSIGHT and its founder and CEO, Farah Bala, PCC.
  • FARSIGHT clients are industry-agnostic and include senior executives across leading corporations and small and medium-sized businesses, entrepreneurs and creatives.
  • FARSIGHT services include, but are not limited to:
    Transformation Partnerships: Bespoke long term programming including leadership workshops, coaching, and strategy consulting
    To learn more about FARSIGHT, please visit www.gofarsight.com or contact [email protected]

PCC Launches 'Sole Marketing'

Retrieved on: 
Wednesday, January 3, 2024

METUCHEN, N.J., Jan. 3, 2024 /PRNewswire/ -- Save time and deliver better patient care while you improve the practice's bottom line. Sole Marketing, developed by Podiatry Content Connection uses the latest technology with communication, reminders, and patient education to drive orthotic sales. Orthotics correct and protect the body's biomechanics, reducing foot, ankle, leg, and even back pain. The system provides a turn-key approach, not adding more work for podiatry practices.

Key Points: 
  • Sole Marketing, developed by Podiatry Content Connection uses the latest technology with communication, reminders, and patient education to drive orthotic sales.
  • Orthotics correct and protect the body's biomechanics, reducing foot, ankle, leg, and even back pain.
  • Our Sole Marketing system connects the podiatrist with the patient and promotes proper care, " says PCC National Director Randy Rosler.
  • "PCC has created a systematic marketing approach to promoting custom orthotics.

Octapharma Announces Availability of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Retrieved on: 
Wednesday, January 3, 2024

PARAMUS, N.J., Jan. 3, 2024 /PRNewswire/ -- Octapharma USA has announced Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex®) is now available. The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

Key Points: 
  • The new non-activated four factor prothrombin complex concentrate (4F-PCC), approved by the U.S. Food and Drug Administration (FDA) this summer, is indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.
  • Octapharma has the Balfaxar® production flexibility to ensure consistent supply for hospitals and medical providers.
  • "Octapharma has the production flexibility to ensure consistent supply for hospitals and medical providers now and in the future.
  • Balfaxar® met the primary endpoint of hemostatic efficacy in patients on a vitamin K antagonist undergoing urgent surgery with significant bleeding risk.

WuXi XDC Enters into Partnership Agreement with IntoCell, Enabling Clients to Accelerate ADC Discovery and Development

Retrieved on: 
Wednesday, January 3, 2024

Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.

Key Points: 
  • Under the agreement, IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate (OHPASTM) Linker and novel Camptothecin drugs called NexatecansTM, a new class of OHPAS-able Camptothecins.
  • WuXi XDC will provide fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services.
  • This synergy will empower clients of both parties to accelerate PCC (Pre-clinical candidates) selection further, develop more next-generation ADCs and other bioconjugates, and expedite the CMC development process.
  • It demonstrates WuXi XDC's platform development strategy, namely to grow continually and evolve to help our clients to accelerate and transform the discovery, development and manufacturing of ADCs and other bioconjugates. "

Walden Macht & Haran LLP Files Lawsuit Against NYU Langone Health on Behalf of World-Renowned Cancer Researcher for Unlawful Termination

Retrieved on: 
Friday, November 17, 2023

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.

Key Points: 
  • NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- oday, the law firm of Walden Macht & Haran LLP served New York University and NYU Langone Health with a lawsuit in “response to the precipitous and unlawful decision to terminate” Benjamin Neel’s, MD, PhD (“Dr.
  • Dr. Neel may be the first fired for pro-Israel and anti-antisemitic re-posts on X, the social media site formerly known as Twitter.
  • According to the lawsuit, Dr. Neel “became a political casualty of NYULH’s effort to terminate” the physician who posted pro-Hamas content.
  • Partner Milton Williams leads the Walden Macht & Haran team representing Dr. Neel and includes senior counsel Daniel Chirlin and associate James Meehan.